ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 1291 • ACR Convergence 2025

    Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures

    Lauren Robinson1, Lusine Ambartsumyan2, Emily Willis3, Aybuke Gunalp4, Simone Appenzeller5, Ozgur Kasapcopur6, Sarah Ishaq7, Natalia Vasquez Canizares8 and Suzanne Li9, 1Hospital for Special Surgery, New York, NY, 2Seattle Children's Hospital, Seattle, WA, 3Royal Manchester Children's Hospital, Manchester, United Kingdom, 4Cerrahpasa Medicine School, Cerrahpasa, Istanbul, Turkey, 5Unicamp, Campinas, São Paulo, Brazil, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 7Osteopathic Medicine , Touro College of Osteopathic Medicine, New York, NY, 8Children's Hospital at Montefiore, New York, NY, 9Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

    Background/Purpose: Gastrointestinal (GI) tract involvement is nearly universal in patients with systemic sclerosis (SSc) leading to significant morbidity and mortality. In a North American juvenile…
  • Abstract Number: 0695 • ACR Convergence 2025

    Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction

    Jennifer Elise Abdalla1, Yuichiro Okushi2, Zoran Popovic2, Heba Wassif2 and Soumya Chatterjee3, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, 3Cleveland Clinic, Richmond Heights, OH

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune rheumatologic disease characterized by fibrosis and vascular complications, which significantly impact various organs, including the heart. Cardiac…
  • Abstract Number: 0161 • ACR Convergence 2025

    Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort

    Madiha Naqsh Siddiqui1, Yen Chen1, Rosemary Gedert2, Suiyuan Huang2, Dinesh Khanna2 and John Varga2, 1University of Michigan, Ann Arbor, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
  • Abstract Number: 2493 • ACR Convergence 2025

    Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs

    Michael Hughes1, Graham Dinsdale2, Aayushi Agnihotri3, Joanne Manning2, Muditha Samaranayaka4, Jonathan Harris2 and Ariane Herrick5, 1The University of Manchester, Manchester, England, United Kingdom, 2Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 3The University of Manchester, Manchester, United Kingdom, 4Salford Royal Hospital, Salford, United Kingdom, 5The University of Manchester, UK, Aberdeen, United Kingdom

    Background/Purpose: Acro-osteolysis (A-O, terminal tuft digit resorption) is characteristic of systemic sclerosis (SSc), occurring in 20-25% of patients (1). Outcome measures are much needed. Following…
  • Abstract Number: 1861 • ACR Convergence 2025

    Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis

    Brecca Miller1, Shervin Assassi2, Maureen Mayes3, alejandro Molina4, Kelly Ruggles5, David Beck6 and Meng Zhang7, 1Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, 2Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 3UT Health Houston Division of Rheumatology, Houston, TX, 4Georgia Institute of Technology, Atlanta, GA, 5NYU Grossman School of Medicine, Brooklyn, NY, 6Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, 7UTHealth Houston Division of Rheumatology, Houston

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
  • Abstract Number: 1214 • ACR Convergence 2025

    Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis

    Sangmee Bae1, Srijana Davuluri2, Brian Lee3, Sean Lim4, Daniela Markovic5, Lorinda Chung2, David Fiorentino6 and Christina Charles-Schoeman7, 1UCLA Rheumatology, Los Angeles, CA, 2Stanford University, Stanford, CA, 3Stanford University, Stanford, 4Stanford University, Palo Alto, 5UCLA, Los Angeles, 6Department of Dermatology, Stanford University Medical Center, Stanford, CA, 7UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy…
  • Abstract Number: 0692 • ACR Convergence 2025

    A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

    Christopher Denton1, Philip Yee2, medha kanitkar3, Charlotte Clarke4, Saiam Ahmed4, Voon H. Ong3, Francesco Del Galdo5, John Pauling6, Marina Anderson7, Muditha Samaranayaka8, Michael Hughes9, Smita Bhat10, Bridget Griffiths11, MAYA BUCH12, David D'Cruz13, Ariane Herrick14, Madelon Vonk15, Nicholas Feemantle4 and Dehbi Hakim-Moulay4, 1University College London, UK, London, United Kingdom, 2Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, 3Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 4University College London, London, United Kingdom, 5University of Leeds, Leeds, United Kingdom, 6North Bristol NHS Trust, Bristol, United Kingdom, 7Lancaster University and NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom, 8Salford Royal Hospital, Salford, United Kingdom, 9Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, 10Ninewells Hospital Dundee, Dundee, Scotland, United Kingdom, 11Ninewells Hospital Dundee, Newcastle, England, United Kingdom, 12UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, 13Kings College London, London, United Kingdom, 14The University of Manchester, UK, Aberdeen, United Kingdom, 15Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Mycophenolate mofetil (MMF) is recommended for skin in diffuse cutaneous (dc)SSc, and for lung fibrosis in SSc, but patients with limited cutaneous (lc)SSc are…
  • Abstract Number: 2491 • ACR Convergence 2025

    High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study

    Marina Dueñas-Ochoa1, Cristina Valero2, Francisco Morandeira3, Juan Carlos Sáez1, Maryia Nikitsina4, Montserrat Roig Kim5, Laia De Daniel Bisbe5, Esther Vicente-Rabaneda6, Arantza Alfranca1, Miguel A. González-Gay7, Martí Aguilar Coll8, Rosario Garcia Vicuña6, Javier Narváez9 and Santos Castañeda10, 1Hospital La Princesa, Madrid, Spain, 2Hospital de la Princesa, Madrid, Spain, 3Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, 4University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, 5Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, 8Hospital Bellvitge, Barcelona, Spain, 9Hospital Universitario de Bellvitge, Barcelona, Spain, 10Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain

    Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
  • Abstract Number: 1858 • ACR Convergence 2025

    Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.

    Aurélien Chepy1, Marie-Elise Martel1, Solange Vivier1, Meryem Tardivel2, Antonino Bongiovanni2, Marie Mistretta1, Maxime Secq1, Lucile Guilbert3, Eric HACHULLA4, Sylvain Dubucquoi5, David Launay1 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, 2Univ. Lille, BioImaging Center Lille-Nord de France (BICeL), Lille, France., Lille, France, 3CHU Lille, Institut d'Immunologie, Lille, France., Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, 5Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France

    Background/Purpose: Antinuclear autoantibodies (ANA) are robust biomarkers for the diagnosis and prognosis of systemic sclerosis (SSc), but their role in pathogenesis is still uncertain. Recent…
  • Abstract Number: 1037 • ACR Convergence 2025

    Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis

    Zixing Liu1, Adrianne Woods2, Julie Paik2, Laura Hummers2, Scott Zeger1, Ami Shah2 and Ji Soo Kim3, 1Johns Hopkins Biostatistics, Baltimore, MD, 2Johns Hopkins Rheumatology, Baltimore, MD, 3Johns Hopkins, Baltimore, MD

    Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
  • Abstract Number: 0691 • ACR Convergence 2025

    Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis

    Brian Lee1, Shufeng Li1, Srijana Davuluri2, Jennifer Lee1 and Lorinda Chung2, 1Stanford University, Stanford, 2Stanford University, Stanford, CA

    Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
  • Abstract Number: 0568 • ACR Convergence 2024

    Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype

    Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX

    Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
  • Abstract Number: 0713 • ACR Convergence 2024

    Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype

    Naveen Kalavar1, Michael Hughes2, Walter Morales3, Ami Shah4, Elizabeth Volkmann5, Roshan Dongre6, Mark Pimentel7, Laura Hummers8 and Zsuzsanna McMahan9, 1University of Texas Health Science Center, Houston, TX, 2University of Manchester, Manchester, United Kingdom, 3Cedars-Sinai, Los Angeles, CA, 4Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 5University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, 6Methodist Hospital, Houston, TX, 7Cedars-Sinai, Los Angeles, 8Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 9UTHealth Houston Division of Rheumatology, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease that negatively impacts internal organ function, including the gastrointestinal tract. While the etiology of…
  • Abstract Number: 1564 • ACR Convergence 2024

    Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis

    Camille Zander1, Sébastien De Almeida Chaves1, Eva Bories2, Martin MICHAUD Martin3, Grégoire Prevot1, Antoine Yrondi1 and Grégory Pugnet4, 1CHU Toulouse, Toulouse, France, 2Clinique Monie, Toulouse, France, 3Clinique St Exupery, Toulouse, France, 4Toulouse Rangueil University Hospital, Toulouse, France

    Background/Purpose: Systemic sclerosis (SSc) is a severe autoimmune connective-tissue disease characterized by vasculopathy, immune activation, and subsequent fibrosis of skin, lungs, heart, kidney or gastrointestinal…
  • Abstract Number: 1817 • ACR Convergence 2024

    Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin

    Chanhyuk Park1, Helen Jarnagin2, Asmaa Mohamed3, Yina Huang3, Michael Whitfield4 and Patricia Pioli1, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth, Lebanon, 4Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology